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CASE PRESENTATION
A 63-year-old male with a past medical history significant
for hypertension for 12 years, stage 3 chronic kidney
disease (baseline serum creatinine concentration,
1.4 mg/dl; estimated glomerular filtration rate, 54 ml/min)
secondary to hypertensive nephrosclerosis presented with
generalized malaise and weakness for 2 weeks. He was
referred for admission to the hospital for evaluation of
renal dysfunction.
Three months before this admission, he was treated
with naproxen 500 mg per day for bilateral knee pain
owing to degenerative joint disease. After 2 weeks of
therapy, he developed epigastric pain with anorexia,
vomiting, and hematemesis. He underwent upper
endoscopy, which revealed esophageal, gastric, and
duodenal erosions and ulcerations. Serum creatinine
concentration was 2.3 mg/dl. Naproxen was discontinued,
esomeprazole 40 mg per day was initiated as anti-acid
therapy and a liter of normal saline was administered
intravenously. Two days later, the serum creatinine
concentration returned to baseline (1.4 mg/dl) and the
patient was discharged home on esomeprazole and
tramadol/acetaminophen.
On presentation to the hospital, blood pressure was
142/88 mm Hg, pulse 100/min, temperature 98.9 degrees
F, and respiratory rate 18/min. The conjunctivae were pale
with anicteric sclera. Heart and lung examination was
unremarkable except for a grade 1/6 systolic ejection
murmur over the left sternal border. The abdomen had
minimal epigastric tenderness, and there was trace edema
in the ankles. There was no skin rash, petechiae, or
purpura. Medications included amlodipine 10 mg daily,
esomeprazole 40 mg daily, diazepam 2.5 mg daily,
tramadol/acetaminophen 100 mg twice daily, and calcitriol
1 mcg every other day.
Admission laboratory data are noted in Table 1. The
remaining laboratory values, including liver function tests
and coagulation profile were within normal range. There
was no peripheral eosinophilia. Urinalysis was notable for
specific gravity, 1.015; pH, 6.0; trace blood; 1þ protein;
and trace leukocyte esterase. Examination of the urine
sediment revealed 2–5 dysmorphic red blood cells/high-
power field, 2–5 white blood cells/high-power field; few
renal tubular epithelial cells; no cellular or granular casts
were present. Urine eosinophils (Wright stain) were
negative. Fractional excretion of sodium was 1.8%
whereas spot urine protein/creatinine ratio was 0.65 mg/g.
A sonogram of kidneys demonstrated slightly echogenic
but normal-sized kidneys without hydronephrosis. The
patient was administered 2 Liters of normal saline and all
medications except amlodipine were held. Despite this,
the serum creatinine concentration rose the next day to
5.2 mg/dl, whereas urine output was 550 ml for the day.
A kidney biopsy was performed for non-oliguric acute
kidney injury.
PATHOLOGIC FINDINGS
Light microscopic examination revealed 15 glomeruli, none
of which were sclerotic. The glomeruli showed no significant
abnormalities (Figure 1). No cellular or fibrous crescents
were present. The blood vessels revealed mild intimal and
medial thickening. There was a diffuse cellular infiltrate,
which consisted of lymphocytes, neutrophils, and eosinophils
(Figure 2). Tubular atrophy and tubulitis were also present.
Immunofluorescence and electron microscopy of glomeruli
did not reveal immune staining or electron dense deposits,
respectively. On electron microscopy, the glomerular en-
dothelial cell fenestrations were normal and foot processes
were intact without effacement.
CLINICAL DIAGNOSIS
Acute interstitial nephritis secondary to esomeprazole.
CLINICAL FOLLOW-UP
Esomeprazole was discontinued in view of the diagnosis of
associated acute interstitial nephritis (AIN). Given the
severity of the kidney dysfunction a short course of oral
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prednisone (40 mg/day) was started and within 6 days the
serum creatinine concentration began to fall. The steroids
were tapered off after 2 weeks; subsequently, his serum
creatinine concentration leveled off at 1.8 mg/dl.
DISCUSSION
Proton pump inhibitors (PPIs) are widely prescribed to treat
numerous acid-related gastrointestinal disorders. In 1989,
omeprazole was introduced as the first effective PPI;
subsequently other drugs in this class have been synthesized
and released into clinical practice. There are five PPIs
currently available in the US market. In 2005, over 43
million prescriptions were written for anti-ulcer therapy in
the United States, and over 8 billion dollars were spent on
PPIs. These drugs work by specifically binding to the Hþ /Kþ
ATPase at the secretory surface of gastric parietal cells,
decreasing both basal and stimulated acid secretion. They are
metabolized by the cytochrome P450 system and their
inactive metabolites are largely excreted in the urine. As less
than 1% of active drug is excreted in the urine, the need for
dose adjustment in the setting of a decreased glomerular
filtration rate and kidney disease is eliminated.1 The fact that
no active drug is excreted in the urine explains the lack of
renal effects of these medications. When studied, omeprazole
had no effect on renal electrolyte balance or urine pH in
healthy male subjects,2 explaining the absence of renal
tubular acidosis in patients treated with PPIs. In general,
renal complications are rare, although the widespread use of
these drugs requires recognition of complications when they
do occur. To date, the only direct adverse renal effects
described are the rare development of hyponatremia (nine
cases) and the increasing number of cases of PPI-AIN. This
article will focus on PPI-induced AIN.
Acute interstitial nephritis is a relatively infrequent cause
of acute kidney injury, and in several large series, represents
approximately 2–3% of all renal biopsies.3–5 In undiagnosed
acute kidney injury with normal-sized kidneys on ultra-
sonography, AIN is more common as noted in up to 27% of
cases on kidney biopsy.6 In a review of the medical literature,
88 case reports of PPI-induced AIN are found. Of these, 76
cases are biopsy proven. This suggests a class effect as all five
of the PPIs clinically available are implicated, with 75 cases
attributed to omeprazole, six to pantoprazole, three to
esomeprazole, two to lansoprazole, and two to rabeprazole.
The higher total number of AIN cases in omeprazole-treated
patients likely represents the longer availability of this agent,
although other factors, such as inherent immunogenicity of
the molecule cannot be ruled out.
The sentinel case report of AIN from omeprazole was
published in 1992.6 Subsequently, several case reports and
series over the next 12 years confirmed the association
between omeprazole and AIN (n¼ 29).7–12 In 2004, other
PPIs were implicated in causing AIN. Two large case series
describing the association of PPIs and AIN are worth noting.
In 2004, Torpey et al.13 published a description of all cases of
biopsy-proven AIN diagnosed at their hospital (United
Kingdom) over a 4-year period from 1995 to 1999. Of a
Figure 1 | Light microscopy reveals normal appearing glomerulus
(arrow) with diffuse cellular infiltrate in the interstitium
(arrowhead) (hematoxylin and eosin stain).
Figure 2 | Light microscopy demonstrates diffuse cellular
infiltrate within the interstitium. The infiltrate consists of
eosinophils (arrowhead) and lymphocytes. Tubulitis is also present
(arrow) (hematoxylin and eosin stain).
Table 1 | Serum laboratory results
Laboratory test Concentration






White blood cell count 7.6 103/ml
Hemoglobin 12.5 g/dl
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total of 24 identified cases of AIN, 14 cases were drug-
induced AIN (60%), of which eight were due to PPIs
(omeprazole¼ 6, lansaprazole¼ 2). The rest of the AIN cases
were caused by an non-steroidal anti-inflammatory drugs
(n¼ 4), amoxacillin (n¼ 1), and warfarin (n¼ 1). Most
patients presented with nonspecific symptoms and all
recovered kidney function to some degree, but most were
left with some level of chronic kidney disease. Recently, 15
cases of AIN associated with PPIs (14 omeprazole, one
pantoprazole) were published by investigators in the Auck-
land region of New Zealand over a 3-year period
(2002–2005).14 Twelve out of 15 cases were biopsy proven;
time from initiation of drug to AIN ranged from 10 days to
18 months. Although all of the patients recovered kidney
function, 12/14 patients were left with chronic kidney disease.
Additionally, based on data from the Centre for Adverse
Reactions Monitoring (CARM) in New Zealand, PPIs are
now the most common cause of drug-induced AIN in their
region (32%), with an incidence of one in 12 500 patient
years.
The largest report to date documenting the association of
PPIs with AIN was recently published by Geevasinga et al.15
These authors examined the issue of PPI-induced AIN by two
methods. First they retrospectively evaluated all cases of
biopsy-proven AIN noted in two Australian teaching
hospitals over a period of 10 years (1993–2003). The cases
were evaluated for demographics, clinical parameters (symp-
toms/signs, type of PPI, concurrent medications, level of
renal function, time to development of AIN) and histo-
pathology (independently reviewed by pathologists). Second,
they queried the Therapeutic Goods Administration (TGA)
database (1991–2004), which is a unit of the Australian
Government Department of Health and Aging that records
spontaneously reported adverse drug effects after they have
been reviewed by the TGA Advisory Committee. Cases were
identified and reviewed for clinical features including
symptoms/signs, type of PPI, level of renal function, and
time to AIN/renal failure (excluding those with concurrent
multiorgan involvement and hospitalized cases). Following
data review, cases were classified as ‘biopsy proven AIN’,
‘suspected interstitial nephritis’, ‘unexplained acute renal
failure’ and ‘renal impairment’. The retrospective review
of hospital data found 28 cases of biopsy-proven AIN, of
which 18 (64%) were due to a PPI (omeprazole¼ 11,
pantoprazole¼ 3, esomeprazole¼ 3, rabeprazole¼ 1). AIN
developed at a mean of 11 weeks following PPI administra-
tion; nonspecific symptoms were common. The TGA
database review noted 34 cases of ‘biopsy-proven AIN’, 10
cases of ‘suspected interstitial nephritis’, 20 cases of
‘unexplained acute renal failure’, and 26 cases of ‘renal
impairment’ associated with PPI therapy. Although the TGA
database suggests an association between PPI therapy and
AIN/AKI, it does not prove cause and effect and therefore
was not used in the calculation of the total number of cases of
PPI-induced AIN (n¼ 88). However, the combination of
these data when examined in the context of previously
reported cases strongly supports a relationship between PPI
therapy and development of AIN.
Classically, AIN associated with methicillin presents with
hypersensitivity as manifested by the triad of symptoms
including fever, rash, and eosinophilia. However, as with
other non-methicillin drugs, this presentation appears to be
less common in patients with PPI-induced AIN. Where
reported, only about 10% had the classic triad of hypersen-
sitivity in the cases published to date. Fewer then 50% of
patients had fever, less then 10% had rash, and approximately
33% had eosinophilia. Most patients had nonspecific
complaints including weakness, fatigue, malaise, and anor-
exia on presentation. In the Geevasinga paper, fatigue and
nausea were present in 39% of patients, whereas 22%
complained of weakness. Figure 3 demonstrates the clinical
and laboratory findings noted with AIN associated with
methicillin, other non-methicillin type drugs (excluding non-
steroidal anti-inflammatory drugs), and PPI-associated AIN
(all cases combined).16 It is notable that the clinical and
laboratory presentation of PPI-induced AIN is similar to that
of the non-methicillin drug-associated AIN.
The timing from initiation of drug to presentation with
kidney involvement appears to be quite variable, occurring
anywhere from 1 week to 9 months. When combining
all of the cases published, symptoms, and/or identification of
AIN occurred on average 9.9 weeks after starting PPI
therapy, not very different than the time frame (11 weeks)
described by Geevasinga et al.15 In patients who were
re-challenged (most often accidental or unsuspected) with
the drug after suspected PPI-induced AIN, symptoms
occurred much more rapidly, usually developing kidney
injury within days.17–20
Diagnosis of PPI-induced AIN should be made based on
renal biopsy given the infrequency of classic signs and
symptoms. Biopsy typically shows an interstitial infiltrate
with or without tubulitis. In the largest case series to date
where biopsy findings were recorded, 88% of patients, but
not all, had eosinophils in the tubulointerstitium.15 Glomer-
uli in most cases were normal, unless there was another
unrelated kidney lesion also present.
Management of PPI-induced AIN is similar to that of
other causes. Key to treatment is the cessation of the
offending agent. In addition to drug withdrawal, most cases
of PPI-associated AIN were treated with some form of
corticosteroid therapy. The debate about the use of steroids
in this disorder remains active and suffers from a lack of
prospective randomized controlled trials. In the largest
retrospective study to date, data from 2598 patients with
AIN was reviewed and there was no statistical difference in
final serum creatinine concentration in those patients treated
with steroids and those who were not. There is some thought,
however, that steroids may play a role in hastening renal
recovery, albeit a similar recovery, compared to no ther-
apy.3,21 Steroids are typically dosed as oral prednisone at
1 mg/kg/day for 1–2 months and tapered rapidly. Mycophe-
nylate mofetil has recently been shown to successfully treat
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AIN from multiple causes (including drugs) in steroid
resistant/dependent cases.22 Thus, mycophenylate mofetil
represents another potential therapeutic option for patients
who are steroid dependent or resistant.
When recognized early, the prognosis of PPI-induced AIN
seems to be quite good. Of note, in all the case reports
published, very few patients required renal replacement
therapy, and none developed end-stage renal disease. Many
patients, however, were left with some renal impairment and
chronic kidney disease. In the study by Geevasinga et al.,15
patients recovered kidney function (Figure 4), however, mean
calculated creatinine clearance was 15.9 ml/min and 11.5 ml/
min lower than baseline at 3 and 6 months, respectively.
Simpson and colleagues also noted incomplete recovery of
kidney function as the mean serum creatinine concentration
increased from a baseline value of 0.94–1.57 mg/dl after PPI-
induced AIN. In other reported cases, patients also recovered
to lower levels of kidney function (serum creatinine
concentration, 1.3 mg/dl) as compared with baseline (serum
creatinine concentration, 1.1 mg/dl).
In conclusion, PPIs are widely prescribed as therapy for
acid-related gastrointestinal diseases. They are clearly asso-
ciated with the development of AIN, with a clinical
presentation typical of non-methicillin type drugs. PPI-
induced AIN should be suspected as a potential cause of
acute kidney injury in patients without an otherwise obvious
cause of kidney dysfunction. Importantly, despite recovery of
kidney function in the majority of cases following drug
withdrawal (7steroids), most patients are left with some
level of chronic kidney disease.
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Figure 3 | Bar graphs demonstrating the clinical features of
methicillin-induced AIN (longitudinal bars), non-methicillin
drug-induced AIN (excluding non-steroidal anti-inflammatory
drugs) (horizontal bars), and PPI-induced AIN (Geevasinga data,
square pattern bars; other PPI cases combined, solid bars).
(Adapted in part from;16 with permission). Abbreviations: AIN, acute
interstitial nephritis; NSAIDs, non-steroidal anti-inflammatory drugs;
PPI, proton pump inhibitor, Hem, hematuria; Pro, proteinuria; RF,




























Figure 4 | Calculated creatinine clearance of 18 patients with
PPI-induced AIN at various time points before, during and after
exposure to PPIs. (Adapted from;15 with permission). Abbreviations:
PPI, proton pump inhibitor.
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